Highlights
Significantly Extended Survival
The addition of palbociclib to maintenance therapy resulted in a median progression-free survival (PFS) of 44.3 months, compared to 29.1 months for standard therapy alone—a 15.2-month absolute improvement.
Palbociclib Extends Progression-Free Survival in HR+/HER2+ Metastatic Breast Cancer: Insights from the PATINA Trial
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.